GET DAILY SIGNALSAzenta (AZTA) Eyes Potential +12% Move to $46 Target
Key Takeaways
- The central target used here is $46 per share, about 12% above the latest close near $40.95.
- This target is not an analyst consensus. Published analyst price targets cluster between roughly $33 and $45 and average around $38, slightly below the current price, so $46 reflects a technical and psychological milestone near the 52-week high of $46.41.
- At $40.95, the stock would need to gain about 12% to reach $46, a modest move relative to its recent swings.
- Supporting factors include recovering revenue, a clean balance sheet, portfolio streamlining, and share repurchases.
- Key risks include persistent GAAP losses, a large goodwill impairment, securities-related investigations, and a valuation that has already outrun most analyst targets.
- For more on the company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated AZTA pages for additional detail.
- Interested in broader market scanning? Explore Trending AI Robots for AI-driven trading ideas across thousands of tickers.
How I Arrived at the $46 Target
Azenta does not currently offer a clean, actionable analyst aggregate that sits meaningfully above the share price. Based on data aggregated by Yahoo Finance and StockAnalysis from six analysts, the average 12-month price target is about $37.80, with individual targets spanning roughly $33 to $44. MarketBeat has at times reported a slightly higher seven-analyst average near $41, but that figure also sits essentially at or below the current quote. In other words, the shares have rallied ahead of published expectations.
Because the consensus mean is below the current price, the $46 objective in this article comes from public technical discussion rather than analyst forecasts. Specifically, $46 approximates the stock's 52-week high of $46.41 reached in early October 2026 and represents a round-number resistance zone where prior buyers stepped back. It is a realistic milestone that is publicly discussed, not a brokerage-derived consensus. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to gauge current momentum.
Current Market Position and Path Toward the Target
With the stock near $40.95, reaching $46 would require upside of roughly 12%, a modest move given Azenta's elevated volatility and a beta near 1.5. The shares have already more than doubled off their 52-week low, so the path to $46 is less about a new fundamental narrative than about sustaining recent momentum through an earnings catalyst and holding above the prior consolidation range.
Fundamentally, Azenta remains loss-making on a GAAP basis, with trailing twelve-month net income near negative $123 million and diluted EPS around negative $2.67. Its forward P/E is elevated near 86, reflecting expectations for future profitability rather than current earnings. That means the stock is valued on revenue growth, margin progress, and a return to sustained profitability.
What Could Support a Move Toward the Target
- Revenue recovery: Fiscal Q3 2026 revenue of $161.2 million rose 12% year over year, with the company returning to a small quarterly profit.
- Balance sheet strength: Azenta held roughly $325–$528 million in cash and marketable securities against only about $54 million in debt, providing flexibility.
- Portfolio focus: The sale of the B Medical Systems business and the acquisition of UK Biocentre simplify operations around core sample-management and multiomics offerings.
- Capital returns: Management repurchased about 2.3 million shares for $50 million under a buyback program, supporting per-share metrics.
- Sector tailwinds: Biopharma research spending and demand for genomic services remain supportive themes for the life sciences tools group.
What Could Prevent the Target From Being Reached
- Persistent losses: A $149.1 million non-cash goodwill impairment and continued GAAP losses weigh on reported results and investor confidence.
- Valuation and expectations: With most analyst price targets below the current quote, the stock must deliver meaningful earnings progress to justify further upside.
- Legal overhang: Multiple securities-fraud investigation announcements have been tied to the company, a sentiment risk that can resurface.
- Macro sensitivity: Rate expectations and risk appetite in small-cap growth names can compress multiples quickly.
- Competition: The life sciences tools space is competitive, and demand cycles tied to biopharma capital spending can turn.
Technical Levels and Market Structure
The most important overhead reference is the 52-week high of $46.41, a level that marked a sharp reversal in October. Round-number resistance sits near $45. On the downside, the $39–$40 zone acted as recent support, with a more durable floor around $35.55. The shares trade above both their 50-day and 200-day moving averages, reflecting an intact longer-term uptrend, but the proximity of the $46 area makes it a clear test of whether buyers are willing to pay at the top of the recent range. From what I see, the technical setup remains constructive but requires confirmation at these higher levels.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms vary. For Azenta, the immediate catalyst is its fiscal fourth-quarter earnings report and forward guidance, followed by any analyst revisions. Investors should also monitor margin progression, free cash flow, the pace of buybacks, sector demand commentary from life sciences peers, and interest-rate and risk-appetite conditions that influence small-cap growth valuations. I’m watching this closely as earnings approach.
AI Daily Buy/Sell Signals
In my own research process, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifting conditions. This AI-driven tool continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market dynamics. It serves as a practical complement to fundamental work, helping identify opportunities and track momentum without replacing independent analysis. For anyone looking to incorporate data-driven signals into their routine, it offers a straightforward way to scan and monitor positions efficiently.
Final Assessment
The question of whether Azenta can reach $46 is not about analyst upside — the average analyst target sits below the current price — but about whether the stock can reclaim its 52-week high. A 12% move is modest by Azenta's historical volatility, and the company has real supports in recovering revenue, a strong balance sheet, portfolio focus, and buybacks. Against that, persistent GAAP losses, a large impairment, legal overhangs, and a valuation that has outrun consensus targets argue for caution. Reaching $46 will likely depend on the next earnings report, guidance, and the stock's ability to hold its recent breakout levels rather than on any single valuation metric.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZTA in upward trend: price rose above 50-day moving average on October 19, 2026
AZTA moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on AZTA as a result. In 60 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for AZTA just turned positive on November 09, 2026. Looking at past instances where AZTA's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
Following a +9.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in 214 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 130 of 177 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for AZTA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AZTA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.136) is normal, around the industry mean (4.964). P/E Ratio (-14.558) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (4.143). Dividend Yield (0.010) settles around the average of (0.005) among similar stocks. P/S Ratio (2.485) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of automation, vacuum and instrumentation solutions
Industry PharmaceuticalsOther
Advertisement